Loading: 100%
Profit & Loss StatementP&L data quality: 0% (?)
edit
No data available yet
Loading data...
No data available for the original financial statements for the selected time periods. You can change the selected time periods by clicking on 'data' on the top right.
Standardised statements can't be displayed.
Reasons:
- It is not known how cost items are reported in the original P&L
- Not all line items from the original statement have been associated with a standardised figure (20 items missing)
No data available for the selected time periods
in million USD FY '09FY '10FY '11FY '12FY '13FY '14FY '15
Product sales, net
28
61
181
255
143
187
137
License fees and service revenue
10
13
12
13
12
0
26
Total revenues
38
74
193
268
156
187
163
Cost of product sales (excludes amortization and impairment of intangible assets)
8
17
34
47
29
27
28
Selling, general and administrative
34
49
72
90
99
97
87
Research and development
21
57
27
42
47
70
51
Amortization and impairment of intangible assets
4
4
4
9
20
24
38
Total operating costs and expenses
67
127
136
187
195
218
203
Loss from operations
-29
-53
57
81
-39
-32
-41
Interest expense, net
0
0
0
0
-2
-9
-9
Change in fair value of contingent consideration related to acquisitions
0
0
0
0
3
1
1
Change in fair value of common stock warrant liability
8
3
-3
0
0
0
0
Other (expense) income, net
1
1
0
0
1
-4
-1
Total other (expense) income
0
0
-3
-1
2
-12
-10
Loss before income taxes
-20
-49
54
80
-37
-44
-50
Provision for income taxes
0
0
-4
14
-25
-2
0
Net (loss) income
-20
-49
50
0
0
0
0
Net loss attributable to non-controlling interest
1
0
0
0
0
0
0
Net loss
-19
0
0
94
-62
-46
-51
Remarks
restated on Nov 30, -1 n/a
calculated values,
restated on Nov 30, -1 n/a
calculated values,
restated on Mar 12, 2014 n/a
calculated values,
restated on Mar 13, 2015 n/a
calculated values,
restated on Mar 14, 2016 n/a
calculated values,
restated on Nov 30, -1 n/a
calculated values,
restated on Nov 30, -1 n/a
calculated values,
Balance SheetBS data quality: 0% (?)
edit
No data available yet
Loading data...
No data available for the original financial statements for the selected time periods. You can change the selected time periods by clicking on 'data' on the top right.
Standardised statements can't be displayed.
Reason:
- Not all line items from the original statement have been associated with a standardised figure (44 items missing)
No data available for the selected time periods
in million USD FY '09FY '10FY '11FY '12FY '13FY '14FY '15
Assets
Cash and cash equivalents
n/a
54
121
140
156
130
140
Marketable securities
n/a
42
40
3
3
3
0
Accounts receivable, net of allowance for doubtful accounts of $120 and $120, respectively
n/a
21
52
92
49
71
30
Other receivables
n/a
0
0
0
8
5
13
Inventories
n/a
4
11
14
14
9
4
Prepaid expenses and other assets
n/a
1
2
3
3
4
4
Deferred tax assets
n/a
0
0
12
2
0
0
Total current assets
n/a
122
226
265
235
222
191
Investments
n/a
9
9
0
0
0
0
Property and equipment, net of accumulated depreciation
n/a
3
3
3
2
1
1
Intangible assets, net of accumulated amortization
n/a
30
42
200
231
230
190
Goodwill
n/a
0
0
7
19
18
18
Deferred tax assets
n/a
0
0
23
0
0
0
Other assets
n/a
0
1
7
13
18
19
Total assets
n/a
164
281
505
499
490
419
Liabilities and owners' equity
Accounts payable and other accrued liabilities
n/a
39 38704000
55 54771000
105 105252000
80 79837000
85 84994000
57 56539000
Accrued payroll and benefits
n/a
3 3313000
2 1788000
5 4835000
7 6872000
8 8444000
8 8188000
Deferred revenue
n/a
12 12300000
12 12300000
12 12300000
0 156000
10 9959000
6 6130000
Common stock warrant liability
n/a
4 3904000
0 0
0 0
0 0
0 0
0 0
Drug development liability
n/a
5 5101000
10 9678000
1 856000
3 3119000
1 1141000
0 259000
Acquisition-related contingent obligations
n/a
0 0
0 0
0 0
0 0
5 4901000
5 5227000
Total current liabilities
n/a
63 63322000
79 78537000
123 123243000
90 89984000
109 109439000
76 76343000
Capital lease obligations
n/a
0 40000
0 9000
0 0
0 0
0 0
0 0
Drug development liability, less current portion
n/a
0 0
0 0
11 11377000
15 14623000
15 14644000
14 14427000
Deferred payment contingency
n/a
0 0
0 0
2 2287000
0 0
0 0
0 0
Deferred revenue, less current portion
n/a
25 25495000
14 14029000
0 0
0 0
0 0
0 383000
Acquisition-related contingent obligations
n/a
0 0
0 0
0 0
8 8329000
2 2441000
1 1439000
Deferred tax liability
n/a
0 0
0 0
0 0
7 7168000
7 6569000
7 6779000
Other long-term liabilities
n/a
0 298000
0 298000
4 4367000
6 5965000
6 6088000
7 7444000
Revolving line of credit
n/a
0 0
0 0
75 75000000
0 0
0 0
0 0
Convertible senior notes
n/a
0 0
0 0
0 0
91 91480000
96 96298000
99 99377000
Total liabilities
n/a
89 89155000
93 92873000
216 216274000
218 217549000
235 235479000
206 206192000
Commitments and contingencies
n/a
0 0
0 0
0 0
0 0
0 0
0 0
Preferred stock
n/a
0 0
0 0
0 0
0 0
0 0
0 0
Common stock, $0.001 par value; 175,000,000 shares authorized; 68,228,935 and 65,969,699 issued and outstanding at December 31, 2015 and 2014, respectively
n/a
0 51000
0 59000
0 60000
0 64000
0 66000
0 68000
Additional paid-in capital
n/a
385 384757000
453 452761000
464 463710000
518 518144000
539 538553000
552 552108000
Accumulated other comprehensive loss
n/a
0 -92000
0 -227000
0 273000
1 894000
-1 -850000
-5 -5319000
Accumulated deficit
n/a
-310 -310400000
-262 -261883000
-175 -175485000
-238 -237619000
-283 -283338000
-334 -334123000
Less: Treasury stock at cost: 0 and 363,055 shares at December 31, 2012 and 2011, respectively
n/a
0 0
-3 -2926000
0 0
0 0
0 0
0 0
Total stockholders’ equity
n/a
74 74476000
188 187907000
289 288681000
282 281606000
255 254554000
213 212857000
Total liabilities and stockholders’ equity
n/a
164 163631000
281 280780000
505 504955000
499 499155000
490 490033000
419 419049000
Remarks restated on n/a restated on Nov 30, -1 n/a restated on Nov 30, -1 n/a restated on Mar 12, 2014 n/a restated on Mar 13, 2015 n/a restated on Nov 30, -1 n/a restated on May 6, 2016 n/a
Cash Flow StatementCF data quality: 0% (?)
edit
No data available yet
Loading data...
No data available for the original financial statements for the selected time periods. You can change the selected time periods by clicking on 'data' on the top right.
Standardised statements can't be displayed.
Reason:
- Not all line items from the original statement have been associated with a standardised figure (59 items missing)
No data available for the selected time periods
in million USD FY '09FY '10FY '11FY '12FY '13FY '14FY '15
Net loss
-20
-49
50
94
-62
-46
-51
Amortization of deferred revenue
-9
-12
-12
-12
-12
0
0
Depreciation and amortization
4
5
6
12
22
25
32
Stock-based compensation
7
8
22
15
12
12
12
Fair value of common stock issued for drug license
1
3
0
0
0
0
0
Change in fair value of common stock warrants issued to non-employees
-8
-3
3
0
0
0
0
Accretion of debt discount, recorded to interest expense on 2018 Convertible Notes (Note 15)
0
0
0
0
0
5
5
Amortization of deferred financing costs, recorded to interest expense on 2018 Convertible Notes (Note 15)
0
0
0
0
0
1
1
Bad debt (recovery) expense
0
0
0
0
0
0
0
Provision for inventory obsolescence
0
0
0
0
0
0
0
Loss on disposal of fixed assets
0
0
0
0
0
0
0
Non-cash foreign currency exchange loss (income)
0
0
0
0
1
6
0
Impairment of intangible assets (Note 3(g))
0
0
0
0
1
0
7
Change in fair value of contingent consideration related to Talon and EVOMELA acquisitions (Note 9)
0
0
0
0
-3
-1
-1
Change in fair value of Allos deferred development costs and deferred payment contingency (Note 16)
0
0
0
0
-3
0
0
Research and development expense recognized for BELEODAQ in-license milestone achievement (Note 17(b)(x))
0
0
0
0
0
8
0
Accounts receivable, net
1
-13
-31
-34
43
-22
40
Other receivables
0
0
0
0
0
2
-7
Inventories
-1
-1
-7
4
2
4
2
Prepaid expenses and current portion of other assets
0
0
-7
9
0
-1
0
Deferred tax assets
0
0
0
-35
33
2
0
Other assets
0
0
0
0
-9
-13
-2
Accounts payable and other accrued obligations
7
22
16
24
-24
5
-28
Accrued payroll and benefits
0
0
-2
-10
0
2
0
Drug development liability
1
1
4
2
-6
-2
-1
Landlord contributions to tenant improvements
0
1
0
0
0
0
0
Deferred revenue
-1
16
0
0
0
10
-4
Deferred tax liability
0
0
0
0
0
-1
0
Other long-term liabilities
0
0
1
1
2
0
1
Net cash provided by (used in) operating activities
-18
-23
43
72
-2
-4
7
Redemption of mutual funds
26
32
18
72
0
0
0
Purchase of equity securities (Note 10)
0
-41
-17
-26
0
0
0
Purchases of property and equipment
-1
-2
0
0
0
-1
0
Purchases of available-for-sale securities
0
0
0
-2
0
0
0
Proceeds from Sale of Available-for-sale Securities
0
0
0
0
0
4
3
Acquisition
-31
0
0
-133
0
0
0
Net cash provided by (used in) investing activities
-6
-10
1
-115
-14
-22
3
Proceeds from issuance of common stock and warrants, net of related offering costs and expenses
96
0
0
0
0
0
0
Proceeds from Mundipharma related to FOLOTYN collaboration (Note 16)
0
0
25
0
7
0
0
Proceeds from exercise of stock options
1
3
5
6
4
2
1
Repurchase of stock options pursuant to tender offer
-3
0
0
0
0
0
0
Proceeds from sale of stock under employee stock purchase plan
0
1
1
1
0
1
1
Purchase of treasury stock
0
0
-3
-9
-2
0
0
Purchase and retirement of restricted stock to satisfy employee tax liability at vesting
0
0
-4
-1
-2
-2
-1
Payment of stock dividend
0
0
0
-9
0
0
0
Repayment of capital leases
0
0
0
0
0
0
0
Proceeds from revolving line of credit (Note 14)
0
0
0
125
100
0
0
Repayment of revolving line of credit (Note 14)
0
0
0
-50
-175
0
0
Proceeds from 2018 Convertible Notes (Note 15)
0
0
0
0
120
0
0
Deferred financing costs (Note 15)
0
0
0
-1
-5
0
0
Proceeds from sale of common stock warrants for 2018 Convertible Notes issuance (Note 15)
1
0
0
0
13
0
0
Purchase of common stock call options related to 2018 Convertible Notes issuance (Note 15)
0
0
0
0
-26
0
0
Net cash provided by financing activities
96
4
24
61
35
1
1
Effect of exchange rates on cash and equivalents
0
0
0
0
-2
-2
-1
Net (decrease) increase in cash and equivalents
72
-29
68
18
17
-26
10
Remarks
restated on Nov 30, -1 n/a
calculated values,
restated on Nov 30, -1 n/a
calculated values,
restated on Mar 12, 2014 n/a
calculated values,
restated on Mar 13, 2015 n/a
calculated values,
restated on Mar 14, 2016 n/a
calculated values,
restated on Nov 30, -1 n/a
calculated values,
restated on Nov 30, -1 n/a
calculated values,